基于RNA测序的多发性骨髓瘤预后基因标签的构建
研究利用癌症基因组图谱多发性骨髓瘤RNA测序数据集(MMRF-CoMMpass,n=412)经四重严格过滤筛选与生存显著相关的基因,在独立数据集GSE24080(559例初诊患者)中验证可重复性,最终以CCT2、CKS1B、PRKDC、NONO和UBE2A五个可重复基因构建RNA测序预后标签,并在五个独立数据集(共1461例)中外部验证。该标签在训练与验证数据集中均能稳健区分低危与高危患者(Ps ≤ 0·001),且独立于并优于常规预后因素(β2微球蛋白、白蛋白、年龄和性别)(Ps ≤ 0·01),在不同治疗方案组中均能预测临床结局(Ps ≤ 0·001)。
要点
- 基于CCT2、CKS1B、PRKDC、NONO和UBE2A五个可重复基因构建RNA测序预后标签。
- 训练集与验证集中均能稳健区分低危与高危患者(Ps ≤ 0·001)。
- 该标签独立于并优于β2微球蛋白、白蛋白、年龄和性别等常规预后因素(Ps ≤ 0·01)。
核心结论
- 基于五个可重复基因(CCT2、CKS1B、PRKDC、NONO和UBE2A)的RNA测序预后标签在训练和验证数据集中均能稳健区分低危与高危多发性骨髓瘤患者(Ps ≤ 0·001)。
- 该标签独立于并优于常规多发性骨髓瘤预后因素(β2微球蛋白、白蛋白、年龄和性别)(Ps ≤ 0·01),且在不同治疗方案组中均能预测临床结局(Ps ≤ 0·001)。
研究设计与样本
- 在癌症基因组图谱多发性骨髓瘤RNA测序数据集(MMRF-CoMMpass,n=412)中通过包含四重严格过滤的流程检测与生存显著相关的基因。
- 在含559例初诊多发性骨髓瘤患者的独立数据集GSE24080中检查所选基因的可重复性。
- 基于训练数据集(MMRF-CoMMpass)最终基因重建RNA测序预后标签,并在五个独立数据集(GSE2658、GSE13624、GSE9782、GSE6477和GSE57317,共1461例多发性骨髓瘤病例)中进行外部验证。
主要发现
- 最终以五个可重复基因CCT2、CKS1B、PRKDC、NONO和UBE2A重建RNA测序预后标签。
- 该标签在训练和验证数据集中均能稳健区分低危与高危患者(Ps ≤ 0·001)。
- 该标签独立于并优于常规多发性骨髓瘤预后因素(β2微球蛋白、白蛋白、年龄和性别)(Ps ≤ 0·01)。
- 治疗方案对该RNA测序标签无影响,该标签在各治疗组中均成功预测临床结局(Ps ≤ 0·001)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Several prognostic gene signatures have been developed to predict the clinical outcome in patients with multiple myeloma (MM). The most salient disadvantage of the previous signatures is their non-reproducibility in external datasets. Given the disadvantages and the superiority of RNA sequencing over microarrays in transcriptome profiling to produce more reliable outputs, we sought to develop a reproducible RNA sequencing-based prognostic gene signature for MM. Genes significantly associated with survival were detected in The Cancer Genome Atlas (TCGA) MM RNA sequencing dataset (MMRF-CoMMpass) (n = 412) through a strict pipeline containing four rigid filters. The reproducibility of the selected genes was checked in an independent dataset (GSE24080), containing 559 newly diagnosed patients with MM. The RNA sequencing-based prognostic signature was reconstructed based on the final genes in the training dataset (MMRF-CoMMpass) and externally validated in five independent datasets (i.e. GSE2658, GSE13624, GSE9782, GSE6477 and GSE57317), containing 1461 MM cases. The RNA sequencing-based signature was reconstructed using finally five reproducible genes: CCT2, CKS1B, PRKDC, NONO and UBE2A. This signature was able to robustly discriminate between low- and high-risk patients in both training and validation datasets (Ps ≤ 0·001). Our signature was also independent of and more powerful than the routine MM prognostic factors (i.e. β2-microglobulin, albumin, age and sex) (Ps ≤ 0·01). Treatment regimens had no effect on RNA sequencing-based signature insofar as this signature succeeded in predicting the clinical outcome in various treatment groups (Ps ≤ 0·001).
引用
- Zamani-Ahmadmahmudi M, Nassiri SM, Soltaninezhad F, et al. Development of an RNA sequencing-based prognostic gene signature in multiple myeloma. Br J Haematol. 2020. PMID: 32410217. doi:10.1111/bjh.16744
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。